BioSpace News Archive

Annovis Bio, Inc. today announced second quarter financial results for the quarter ended June 30, 2022, and reviewed recent accomplishments.

Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announces financial results for the second quarter ended June 30, 2022 and provides a corporate update.

TRACON Pharmaceuticals, Inc. today announced that the company submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1/2 clinical study.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the second quarter ended June 30, 2022.

Vaxart, Inc. (NASDAQ: VXRT) today announced that W. Mark Watson was appointed to the Company’s Board of Directors, effective August 4, 2022.

Astellas Pharma US, Inc. (“Astellas”) today announced the winner of the sixth annual C 3 (Changing Cancer Care) Prize, a global challenge that funds and advances the best non-treatment ideas to improve cancer care for patients.

Heska Corporation (NASDAQ: HSKA; “Heska” or the “Company”), a leading global provider of advanced veterinary diagnostic and specialty solutions, reported financial results in two segments ( North America and International) for its second quarter ended June 30, 2022.

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, has appointed Diagnostic Oncology CRO, LLC (“DXOCRO”) to undertake development and clinical validation studies for its Nu.Q® product portfolio in the United States.

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its Applied Biosystems HIV-1 Genotyping Kit with Integrase, a research use only assay that examines positive samples of human immunodeficiency virus (HIV) to identify genetic variants that resist common antiretrovial therapeutics.

Koneksa , a healthcare technology company pioneering digital biomarkers, today announced The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a second research grant to evaluate Parkinson’s disease (PD) progression using digital measures.